Provectus Biopharmaceuticals Profit Margin

The latest profit margin for PVCT is -9775.33% as of March 2026. That compares with -2004.36% in the prior-year period — down 387.7% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Provectus Biopharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, PVCT's profit margin moved from -2004.36% to -9775.33% — a 387.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Provectus Biopharmaceuticals's valuation or profitability profile.

Against Healthcare companies, PVCT currently prints -9775.33% for profit margin, while the sector average sits near 15.29%. That is roughly 64020.7% below the sector mean. Large gaps often invite a closer look at Provectus Biopharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Provectus Biopharmaceuticals converts resources into returns. At -9775.33%, PVCT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -2004.36% in the prior-year period — down 387.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PVCT's profit margin (-9775.33%), review year-over-year change from -2004.36%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.